DZ3286A1 - Nouvelle utilisation - Google Patents

Nouvelle utilisation

Info

Publication number
DZ3286A1
DZ3286A1 DZ013286A DZ013286A DZ3286A1 DZ 3286 A1 DZ3286 A1 DZ 3286A1 DZ 013286 A DZ013286 A DZ 013286A DZ 013286 A DZ013286 A DZ 013286A DZ 3286 A1 DZ3286 A1 DZ 3286A1
Authority
DZ
Algeria
Prior art keywords
new use
new
Prior art date
Application number
DZ013286A
Other languages
English (en)
Inventor
Gerald Voss
Original Assignee
Smithkline Beecham Biologicals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002200A external-priority patent/GB0002200D0/en
Priority claimed from GB0009336A external-priority patent/GB0009336D0/en
Priority claimed from GB0013806A external-priority patent/GB0013806D0/en
Priority claimed from PCT/EP2000/005998 external-priority patent/WO2001000232A2/fr
Application filed by Smithkline Beecham Biologicals filed Critical Smithkline Beecham Biologicals
Application granted granted Critical
Publication of DZ3286A1 publication Critical patent/DZ3286A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DZ013286A 2000-01-31 2001-01-29 Nouvelle utilisation DZ3286A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0002200A GB0002200D0 (en) 2000-01-31 2000-01-31 Novel use
GB0009336A GB0009336D0 (en) 2000-04-14 2000-04-14 Novel use
GB0013806A GB0013806D0 (en) 2000-06-06 2000-06-06 Novel use
PCT/EP2000/005998 WO2001000232A2 (fr) 1999-06-29 2000-06-28 Vaccin
PCT/EP2001/000944 WO2001054719A2 (fr) 2000-01-31 2001-01-29 Nouvelle utilisation

Publications (1)

Publication Number Publication Date
DZ3286A1 true DZ3286A1 (fr) 2001-08-02

Family

ID=27255504

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013286A DZ3286A1 (fr) 2000-01-31 2001-01-29 Nouvelle utilisation

Country Status (23)

Country Link
US (3) US20030158134A1 (fr)
EP (1) EP1251870A2 (fr)
JP (1) JP2003529559A (fr)
KR (2) KR20070073987A (fr)
CN (1) CN1326873C (fr)
AP (1) AP2002002592A0 (fr)
AU (1) AU783005B2 (fr)
BG (1) BG106964A (fr)
BR (1) BR0107972A (fr)
CA (1) CA2398611A1 (fr)
CZ (1) CZ20022643A3 (fr)
DZ (1) DZ3286A1 (fr)
EA (1) EA200200724A1 (fr)
HK (1) HK1051317A1 (fr)
HU (1) HUP0204250A3 (fr)
IL (1) IL150756A0 (fr)
MX (1) MXPA02007413A (fr)
NO (1) NO20023616L (fr)
NZ (1) NZ520327A (fr)
OA (1) OA12168A (fr)
PL (1) PL211762B1 (fr)
SK (1) SK11122002A3 (fr)
WO (1) WO2001054719A2 (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
CA2358385C (fr) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US6982086B2 (en) 2000-02-04 2006-01-03 Duke University Human immunodeficiency virus immunogenic composition
WO2005090392A1 (fr) * 2004-03-16 2005-09-29 Inist Inc. Compositions tolerogenes a base de tat et methodes de production et d'utilisation associees
EP1411770A4 (fr) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP1279404A1 (fr) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Utilisation de HIV-1 tat fragments ou dérivés pour activer des cellules présentatrices d'antigènes, pour délivrer des molécules cargo pour la vaccination ou pour le traitement d'autres maladies
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
MXPA04004876A (es) 2001-11-21 2004-07-30 Univ Pennsylvania Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso.
EP1944043A1 (fr) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation.
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1487486B1 (fr) * 2002-03-19 2009-01-14 PowderJect Research Limited Imidazoquinolineamines comme adjuvants dans la vaccination d'adn d'hiv
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
WO2003097675A1 (fr) 2002-05-16 2003-11-27 Bavarian Nordic A/S Proteine hybride des proteines regulateurs de vih/accessoires
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
JP2006504687A (ja) 2002-09-13 2006-02-09 インターツェル・アクチェンゲゼルシャフト Ｃ型肝炎ウイルスペプチドの単離方法
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
WO2004084937A1 (fr) * 2003-03-24 2004-10-07 Intercell Ag Utilisation d'alun et d'un adjuvant induisant une reponse immunitaire du type genere par une th1 pour renforcer des reponses immunitaires
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
WO2005070041A2 (fr) * 2004-01-09 2005-08-04 Morehouse School Of Medicine Vaccin modulateur contre la depletion lymphocytaire induite par la proteine nef du vih
GB0405480D0 (en) 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
WO2006100111A1 (fr) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
WO2008094188A2 (fr) * 2006-07-17 2008-08-07 Anza Therapeutics, Inc. Procédés et compositions utilisant la listeria pour renforcer l'immunogénicité par primo-immunisation
EP2043682B1 (fr) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Vaccin anti-grippal
CN101600453A (zh) * 2006-11-17 2009-12-09 杜克大学 多组分疫苗
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008223951B2 (en) * 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
EP2220217A2 (fr) 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Adénovirus c de la sous-famille simiesque sadv-40, -31, et -34 et leurs utilisations
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
WO2010051367A1 (fr) 2008-10-31 2010-05-06 The Trustees Of The University Of Pennsylvania Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations
NZ595060A (en) 2009-03-23 2013-05-31 Pin Pharma Inc Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CA2762203A1 (fr) 2009-05-29 2010-12-02 Soumitra Roy Adenovirus simien 41 et ses utilisations
EP2643465B1 (fr) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens de la sous-famille e a1321 et ses utilisations
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
EP3052127A1 (fr) 2013-10-04 2016-08-10 PIN Pharma, Inc. Polypeptides immunostimulants dérivés du tat de vih utilisés dans le traitement du cancer
MY186389A (en) 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
CN104001155B (zh) * 2014-06-12 2016-04-13 中山大学 一种Tat蛋白及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3565535A4 (fr) * 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center Systèmes et procédés pour améliorer l'efficacité d'un vaccin
GB2592769B (en) 2020-03-01 2022-05-04 Valneva Austria Gmbh CpG-Adjuvanted SARS-CoV-2 virus vaccine
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスｄｎａベクター及びその使用
WO2023177655A1 (fr) 2022-03-14 2023-09-21 Generation Bio Co. Compositions vaccinales prime-boost hétérologues et méthodes d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
BR9607659A (pt) * 1995-03-08 1998-12-15 Neovacs Composto imunogênio composição processos para preparação de um composto imunogênico de um anticorpo anti-proteína e de um fragmento anticorpo anti-proteína e fragmento
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Also Published As

Publication number Publication date
US20090104229A1 (en) 2009-04-23
US20030158134A1 (en) 2003-08-21
US20050266025A1 (en) 2005-12-01
MXPA02007413A (es) 2004-07-30
PL357210A1 (en) 2004-07-26
CA2398611A1 (fr) 2001-08-02
SK11122002A3 (sk) 2003-01-09
KR100808348B1 (ko) 2008-02-27
KR20070073987A (ko) 2007-07-10
EA200200724A1 (ru) 2003-02-27
NO20023616L (no) 2002-09-17
AP2002002592A0 (en) 2002-09-30
HUP0204250A3 (en) 2005-06-28
PL211762B1 (pl) 2012-06-29
BG106964A (bg) 2004-01-30
KR20020073569A (ko) 2002-09-27
NZ520327A (en) 2004-06-25
CN1419456A (zh) 2003-05-21
IL150756A0 (en) 2003-02-12
OA12168A (en) 2006-05-08
EP1251870A2 (fr) 2002-10-30
AU783005B2 (en) 2005-09-15
CN1326873C (zh) 2007-07-18
NO20023616D0 (no) 2002-07-30
BR0107972A (pt) 2002-11-05
WO2001054719A2 (fr) 2001-08-02
WO2001054719A3 (fr) 2001-12-20
JP2003529559A (ja) 2003-10-07
HUP0204250A1 (hu) 2003-03-28
CZ20022643A3 (cs) 2003-02-12
AU5791001A (en) 2001-08-07
HK1051317A1 (zh) 2003-08-01

Similar Documents

Publication Publication Date Title
DZ3286A1 (fr) Nouvelle utilisation
PT1259508E (pt) Novos biarilcarboxamidas
DE60110386D1 (de) Rasierklingentechnologie
DE60143985D1 (de) Os
DE60118573D1 (de) Druckspeicher
NO20030276D0 (no) Fremgangsmåte
DE60109229D1 (de) Tupfer
DE60117455D1 (de) Sicherungseinheit
DE60139831D1 (de) Sicherung
NO20025533D0 (no) Sulfonamidderivater
NO20025459D0 (no) Sulfonamidderivater
FR2823975B1 (fr) Nouvelle utilisation de pyridoindolone
DE60106687D1 (de) Tupfer
SE0001872D0 (sv) New use
SE0004363D0 (sv) New use
SE0002461D0 (sv) New use
SE0002228D0 (sv) New use
SE0002196D0 (sv) New use
SE0000799D0 (sv) New use
DK1274710T3 (da) Hidtil ukendte heteroaryl-diazabicycloalkaner
SE0002352D0 (sv) New combination
SE0001188D0 (sv) New combination
FIU20000376U0 (fi) Laituri
FIU20000366U0 (fi) Laituri
IS5657A (is) Tengistykki